Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥359.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥22.31B
Enterprise Value¥13.10K
Total Cash (Recent Filing)¥5.71B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Sep 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.97
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.8
Revenue Forecast (FY)¥540.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage (debt Effectively Near Zero)Near-zero debt materially reduces solvency risk and interest burden, giving management structural flexibility to pursue R&D, partnerships or equity raises without immediate refinancing pressure. That balance-sheet optionality supports survival and strategic choices over months.
Prior Revenue And Profitability (2023)A 2023 revenue base (2,350M) and modest net profit (168M) demonstrate the firm previously generated commercial or transaction income and achievable margins. That historic capability indicates assets, products or partnerships that could be redeployed or monetized if operations or markets stabilize.
Improving Cash Burn In 2025 Vs 2024Reduction in cash burn in 2025 versus 2024 signals management has taken steps to curb outflows, a durable operational adjustment. If sustained, lower burn extends runway, reduces near-term financing urgency and provides time to execute strategic pivots or secure partner deals over the coming months.
Bears Say
Revenue Collapsed To Zero In 2024–2025A complete revenue disappearance across two years is a structural red flag: it implies lost customers, ceased product sales or discontinued revenue streams. Without durable revenue restoration, the company's business model cannot cover fixed costs, threatening viability absent new durable income.
Sustained Large Net Losses (~-2.0B Annually)Recurring multi-year losses of ~-2.0B severely erode equity and limit strategic options. Persistent negative profitability reduces reinvestment capacity, increases reliance on external funding or dilution, and raises execution risk for development programs over the medium term.
Deeply Negative Operating And Free Cash FlowLarge negative operating and free cash flows indicate the company cannot self-fund operations or growth. Even with low debt, continued cash burn forces reliance on financing or asset sales, compresses runway, and materially raises the risk of operational disruption within months without durable new funding.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥359.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥22.31B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Sep 09, 2026 which is in 25 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Jun 10, 2026. The company reported -¥7.6 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥7.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.128%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―